Systemic inflammation in COPD in relation to smoking status

Danielius Serapinas, Andrius Narbekovas, Jonas Juškevicius, Raimundas Sakalauskas

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background and aims: Smoking is the main risk factor for the development of chronic obstructive pulmonary disease (COPD) that has been recently defined as a systemic pulmonary inflammatory disease. However, the impact of smoking itself on systemic inflammation in COPD patients has not yet been well established. The aim of our study was to investigate the association between inflammatory markers and smoking status. Material and methods: We compared 202 current smokers, 61 ex-smokers and 57 never-smokers, all COPD patients. Assessments included medical history, spirometry, alpha-1 antitrypsin (AAT) genotyping, serum AAT, C-reactive protein (CRP), tumor necrosis factor (TNF)- &αλπηα;, and soluble tumor necrosis factor receptor (sTNFR)-1 and sTNFR-2 concentrations. Results: AAT and CRP concentrations in smokers (1.75 ± 0.51 g/L and 14.4 [9.5-20.5] mg/L) and ex-smokers (1.69 ± 0.43 g/L and 12.3 [8.7-16.3] mg/L) were higher than in never-smokers (1.49 ± 0.38 g/L and 5.1 [2.5-8.7] mg/L; p <0.05). sTNFR-1 level was higher in smokers than ex-smokers or never-smokers (241.2 pg/mL [145.3-349.4] vs. 213.7 pg/mL [147.1-280.3] and 205.2 pg/mL [125-275]; p <0.05). Conclusions: Our data confirm that smoking is associated with increased levels of AAT, CRP, and sTNFR-1 in COPD patients, an array of systemic inflammation markers that continue to be active even after smoking cessation.

Original languageEnglish
Pages (from-to)214-219
Number of pages6
JournalMultidisciplinary Respiratory Medicine
Volume6
Issue number4
Publication statusPublished - 2011

Fingerprint

alpha 1-Antitrypsin
Chronic Obstructive Pulmonary Disease
Tumor Necrosis Factor Receptors
Smoking
C-Reactive Protein
Inflammation
Receptors, Tumor Necrosis Factor, Type II
Spirometry
Smoking Cessation
Lung Diseases
Tumor Necrosis Factor-alpha
Serum

Keywords

  • Alpha-1 antitrypsin
  • COPD
  • Inflammatory markers

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Systemic inflammation in COPD in relation to smoking status. / Serapinas, Danielius; Narbekovas, Andrius; Juškevicius, Jonas; Sakalauskas, Raimundas.

In: Multidisciplinary Respiratory Medicine, Vol. 6, No. 4, 2011, p. 214-219.

Research output: Contribution to journalArticle

Serapinas, D, Narbekovas, A, Juškevicius, J & Sakalauskas, R 2011, 'Systemic inflammation in COPD in relation to smoking status', Multidisciplinary Respiratory Medicine, vol. 6, no. 4, pp. 214-219.
Serapinas, Danielius ; Narbekovas, Andrius ; Juškevicius, Jonas ; Sakalauskas, Raimundas. / Systemic inflammation in COPD in relation to smoking status. In: Multidisciplinary Respiratory Medicine. 2011 ; Vol. 6, No. 4. pp. 214-219.
@article{0996d36ac2ab4c24b8fa76493446a058,
title = "Systemic inflammation in COPD in relation to smoking status",
abstract = "Background and aims: Smoking is the main risk factor for the development of chronic obstructive pulmonary disease (COPD) that has been recently defined as a systemic pulmonary inflammatory disease. However, the impact of smoking itself on systemic inflammation in COPD patients has not yet been well established. The aim of our study was to investigate the association between inflammatory markers and smoking status. Material and methods: We compared 202 current smokers, 61 ex-smokers and 57 never-smokers, all COPD patients. Assessments included medical history, spirometry, alpha-1 antitrypsin (AAT) genotyping, serum AAT, C-reactive protein (CRP), tumor necrosis factor (TNF)- &αλπηα;, and soluble tumor necrosis factor receptor (sTNFR)-1 and sTNFR-2 concentrations. Results: AAT and CRP concentrations in smokers (1.75 ± 0.51 g/L and 14.4 [9.5-20.5] mg/L) and ex-smokers (1.69 ± 0.43 g/L and 12.3 [8.7-16.3] mg/L) were higher than in never-smokers (1.49 ± 0.38 g/L and 5.1 [2.5-8.7] mg/L; p <0.05). sTNFR-1 level was higher in smokers than ex-smokers or never-smokers (241.2 pg/mL [145.3-349.4] vs. 213.7 pg/mL [147.1-280.3] and 205.2 pg/mL [125-275]; p <0.05). Conclusions: Our data confirm that smoking is associated with increased levels of AAT, CRP, and sTNFR-1 in COPD patients, an array of systemic inflammation markers that continue to be active even after smoking cessation.",
keywords = "Alpha-1 antitrypsin, COPD, Inflammatory markers",
author = "Danielius Serapinas and Andrius Narbekovas and Jonas Juškevicius and Raimundas Sakalauskas",
year = "2011",
language = "English",
volume = "6",
pages = "214--219",
journal = "Multidisciplinary Respiratory Medicine",
issn = "1828-695X",
publisher = "Novamedia s.r.l.",
number = "4",

}

TY - JOUR

T1 - Systemic inflammation in COPD in relation to smoking status

AU - Serapinas, Danielius

AU - Narbekovas, Andrius

AU - Juškevicius, Jonas

AU - Sakalauskas, Raimundas

PY - 2011

Y1 - 2011

N2 - Background and aims: Smoking is the main risk factor for the development of chronic obstructive pulmonary disease (COPD) that has been recently defined as a systemic pulmonary inflammatory disease. However, the impact of smoking itself on systemic inflammation in COPD patients has not yet been well established. The aim of our study was to investigate the association between inflammatory markers and smoking status. Material and methods: We compared 202 current smokers, 61 ex-smokers and 57 never-smokers, all COPD patients. Assessments included medical history, spirometry, alpha-1 antitrypsin (AAT) genotyping, serum AAT, C-reactive protein (CRP), tumor necrosis factor (TNF)- &αλπηα;, and soluble tumor necrosis factor receptor (sTNFR)-1 and sTNFR-2 concentrations. Results: AAT and CRP concentrations in smokers (1.75 ± 0.51 g/L and 14.4 [9.5-20.5] mg/L) and ex-smokers (1.69 ± 0.43 g/L and 12.3 [8.7-16.3] mg/L) were higher than in never-smokers (1.49 ± 0.38 g/L and 5.1 [2.5-8.7] mg/L; p <0.05). sTNFR-1 level was higher in smokers than ex-smokers or never-smokers (241.2 pg/mL [145.3-349.4] vs. 213.7 pg/mL [147.1-280.3] and 205.2 pg/mL [125-275]; p <0.05). Conclusions: Our data confirm that smoking is associated with increased levels of AAT, CRP, and sTNFR-1 in COPD patients, an array of systemic inflammation markers that continue to be active even after smoking cessation.

AB - Background and aims: Smoking is the main risk factor for the development of chronic obstructive pulmonary disease (COPD) that has been recently defined as a systemic pulmonary inflammatory disease. However, the impact of smoking itself on systemic inflammation in COPD patients has not yet been well established. The aim of our study was to investigate the association between inflammatory markers and smoking status. Material and methods: We compared 202 current smokers, 61 ex-smokers and 57 never-smokers, all COPD patients. Assessments included medical history, spirometry, alpha-1 antitrypsin (AAT) genotyping, serum AAT, C-reactive protein (CRP), tumor necrosis factor (TNF)- &αλπηα;, and soluble tumor necrosis factor receptor (sTNFR)-1 and sTNFR-2 concentrations. Results: AAT and CRP concentrations in smokers (1.75 ± 0.51 g/L and 14.4 [9.5-20.5] mg/L) and ex-smokers (1.69 ± 0.43 g/L and 12.3 [8.7-16.3] mg/L) were higher than in never-smokers (1.49 ± 0.38 g/L and 5.1 [2.5-8.7] mg/L; p <0.05). sTNFR-1 level was higher in smokers than ex-smokers or never-smokers (241.2 pg/mL [145.3-349.4] vs. 213.7 pg/mL [147.1-280.3] and 205.2 pg/mL [125-275]; p <0.05). Conclusions: Our data confirm that smoking is associated with increased levels of AAT, CRP, and sTNFR-1 in COPD patients, an array of systemic inflammation markers that continue to be active even after smoking cessation.

KW - Alpha-1 antitrypsin

KW - COPD

KW - Inflammatory markers

UR - http://www.scopus.com/inward/record.url?scp=80054047906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054047906&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 214

EP - 219

JO - Multidisciplinary Respiratory Medicine

JF - Multidisciplinary Respiratory Medicine

SN - 1828-695X

IS - 4

ER -